Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by biggonadson Aug 24, 2022 12:02pm

144 Views

Post# 34917263

AGN's largest shareholder increases ownership position

Algernon’s largest shareholder AlphaNorth has effectively increased their ownership position now up to 13% following the recent announcement of the closing of their private placement generating gross proceeds of $1.4M. Algernon is fully cashed up to rapidly advance clinical trials for their two lead programs, the latter with DMT treatments positioning them as one of the cheapest psychedelic stock on the market. https://www.globenewswire.com/news-release/2022/08/23/2502845/0/en/Algernon-Pharmaceuticals-Largest-Shareholder-AlphaNorth-Asset-Management-Increases-Ownership-Position.html

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter